(JAGX) Jaguar Health, Inc. BCG Matrix Research |
Fully Editable: Tailor To Your Needs In Excel Or Sheets
Professional Design: Trusted, Industry-Standard Templates
Investor-Approved Valuation Models
MAC/PC Compatible, Fully Unlocked
No Expertise Is Needed; Easy To Follow
(JAGX) Jaguar Health, Inc. Complete Analysis Pack
Download Your Competitive Advantage
This Jaguar Health, Inc. BCG Matrix helps you quickly see how the company’s products or business units may fit into the Stars, Cash Cows, Question Marks, and Dogs framework for strategy and capital allocation. The page already shows a real preview of the analysis, so you can review the actual format and content before buying. Purchase the full version to get the complete ready-to-use report.
Stars
Crofelemer cancer therapy diarrhea
Crofelemer is Jaguar Health, Inc.'s clearest Stars candidate in BCG terms: it targets cancer therapy diarrhea, a large oncology supportive-care niche with recurring demand. The asset is still investigational for this use, but it builds on crofelemer's existing FDA approval for HIV-related diarrhea. That gives it the strongest large-market upside in Jaguar Health, Inc.'s portfolio.
Crofelemer short bowel syndrome
Crofelemer for short bowel syndrome with intestinal failure targets a rare U.S. market of about 10,000 to 20,000 patients, where options are limited and care is costly.
That orphan setting can support premium pricing if Jaguar Health, Inc. proves benefit, since SBS-IF often needs long-term specialty treatment and parenteral support.
So this looks like a high-upside Star: small volume, but strong value if clinical data and uptake improve.
Crofelemer congenital diarrheal disorders
Crofelemer’s push into congenital diarrheal disorders fits a Stars label: the target group is ultra-rare, but infants and children face severe, often life-threatening diarrhea and very few approved options. Jaguar Health is seeking pediatric use, and even a small addressable market can matter when the clinical need is so high. If approved, the orphan-style label could carry strong pricing and reimbursement value despite limited patient volume.
Lechlemer cholera
Lechlemer is Jaguar Health's next-gen anti-secretory cholera candidate, aimed at a disease that still causes about 1.3 million to 4.0 million cases and 21,000 to 143,000 deaths a year worldwide. If it works, it could give Jaguar Health a differentiated infectious-disease asset in a market where fast diarrhea control matters.
- High unmet need in endemic regions
- Potentially differentiated mechanism
- Value depends on clinical proof
Crofelemer broader GI expansion
Crofelemer is still a niche HIV diarrhea asset, but Jaguar Health, Inc. is trying to broaden it into larger GI markets. The biggest upside is in indications with far more patients than the current label, such as noninfectious diarrhea, but these remain development-stage bets, not approved revenue drivers.
- Current value: HIV-diarrhea niche
- Expansion target: larger GI pools
- Status: still development stage
- Upside: scalable if trials win
Crofelemer Leads Jaguar's Growth as GI and Orphan Upside Build
Crofelemer is Jaguar Health, Inc.'s strongest Star because it already has FDA approval for HIV-related diarrhea and can expand into larger GI uses. The biggest upside is cancer therapy diarrhea, while short bowel syndrome with intestinal failure adds a rare but high-value orphan market of about 10,000 to 20,000 U.S. patients. Lechlemer also has Star potential in cholera, a global disease with 1.3 million to 4.0 million cases a year.
| Asset | Star case | Key data |
|---|---|---|
| Crofelemer | Lead Star | FDA-approved for HIV diarrhea |
| SBS-IF | Orphan upside | 10,000-20,000 U.S. patients |
| Lechlemer | Pipeline Star | 1.3M-4.0M cholera cases |
What is included in the product
Detailed Word Document
Jaguar Health’s BCG Matrix maps its products into Stars, Cash Cows, Question Marks, and Dogs to guide invest, hold, or divest decisions.
Editable Excel File
One-page Jaguar Health BCG Matrix view highlighting pain points and quadrant priorities for faster decisions
Reference Sources
Provides a credible source trail for Jaguar Health, Inc. claims, helping investors verify assumptions quickly and make better decisions.
Cash Cows
Mytesi HIV diarrhea
Mytesi is Jaguar Health, Inc.'s only approved human product and the main cash cow in its BCG Matrix. It is indicated for symptomatic relief of noninfectious diarrhea in adults with HIV/AIDS on antiretroviral therapy, and recent filings show it remains the company’s core commercial revenue engine. With limited product breadth, Mytesi carries most of Jaguar Health, Inc.'s monetization risk and upside.
Crofelemer adult HIV label
Crofelemer’s adult HIV-associated diarrhea label is Jaguar Health, Inc.’s most mature asset: one FDA-approved adult indication, first cleared in 2012, with a clear clinical role for adults on antiretroviral therapy. Growth is limited, but the label can still support steady prescription revenue because the use case is established and reimbursable.
Canalevia-CA1 canine EID
Canalevia-CA1 is Jaguar Health, Inc.’s FDA conditionally approved veterinary drug for exercise-induced diarrhea in dogs, giving it a clear, niche use case and an established brand position. In BCG terms, it is the closest animal-health cash generator because it already has market access and low direct competition. Jaguar has said the product is its lead dog-health asset, but it has not disclosed 2025/2026 segment revenue for it separately.
Human Health sales channel
Jaguar Health’s Human Health channel is a Cash Cow because Mytesi already has the selling, reimbursement, and specialty-pharmacy setup in place, so new volume can flow through a live commercial system instead of a new launch build. That matters in 2025 because the channel supports one FDA-approved human product, which keeps incremental selling cost lower and margins cleaner than a start-from-zero model.
- Existing reps and reimbursement links
- Lower launch spend for new sales
- Mytesi anchors the channel
Animal Health sales channel
Jaguar Health’s animal-health sales channel is a classic Cash Cow because Canalevia-CA1 serves a narrow veterinary use case with specialized selling and lower promotional spend than broad pet-health brands. That favors repeat, niche revenue more than fast expansion, and the company’s animal-health base stayed centered on prescription veterinary demand through 2025/2026.
- Specialized veterinary sales
- Lower promo complexity
- Recurring niche revenue
- Limited growth, steady base
Jaguar Health’s Cash Cows: Mytesi Drives the Core, Canalevia Adds Niche Value
Cash Cows in Jaguar Health, Inc. are Mytesi and the two mature channels behind it: human health and animal health. Mytesi remains the core revenue engine, while Canalevia-CA1 adds a niche, low-spend veterinary base. Jaguar Health, Inc. did not break out 2025/2026 revenue for either asset separately.
| Asset | Cash Cow role | Latest disclosed fact |
|---|---|---|
| Mytesi | Core | Only approved human product |
| Canalevia-CA1 | Niche | FDA conditionally approved for dogs |
Get Your Copy
Jaguar Health, Inc. Reference Sources
The Jaguar Health, Inc. BCG Matrix preview you see here is the exact same document you’ll receive after purchase. No demo content, no placeholders—just the full, professionally formatted file ready for immediate use. Once purchased, you’ll get the complete version for download, editing, printing, or sharing. What you preview is exactly what you own.
Dogs
Crofelemer IBS-D
Crofelemer’s IBS-D work is still exploratory, and IBS-D remains crowded with approved rivals such as Xifaxan and Viberzi. In the U.S., IBS affects about 10% to 15% of adults, but crofelemer has no clear approved IBS-D position yet. That makes this a low-share, low-certainty "Dog" in Jaguar Health, Inc.'s BCG mix.
Crofelemer idiopathic diarrhea
Crofelemer for idiopathic diarrhea sits in the Question Mark/Dog zone because the label is broad, so it lacks a sharp commercial moat and makes payer pull-through harder. For a small company like Jaguar Health, Inc., that weak fit matters: selling a symptom-based use case needs more marketing reach than the product base usually supports. The market is real, but the route to repeatable adoption is weak.
Crofelemer IBD diarrhea
Crofelemer IBD diarrhea sits in a tough Dog slot: ulcerative colitis and Crohn's disease affect about 3 million U.S. adults, but specialist rivals already crowd this space. Jaguar Health, Inc. still lacks a dominant share, so the chance of winning broad use is low. The market matters clinically, yet it remains hard to scale into a leader.
Canine chemotherapy diarrhea
Jaguar Health, Inc.’s canine chemotherapy diarrhea work targets a niche, low-volume market. With roughly 90 million U.S. dogs and cancer affecting about 1 in 4 over a lifetime, the pool that actually needs chemo-related diarrhea treatment stays small and scattered across many oncology clinics. Even if development progresses, that fragmentation caps scale, so this sits closer to a Question Mark than a Star in the BCG Matrix.
- Small, fragmented vet oncology market
- Limited scale even with approval
- BCG fit: Question Mark
Other exploratory GI uses
Jaguar Health, Inc. keeps several crofelemer GI uses in exploratory work, but they still have no proven market traction and remain cash-using bets. With only 1 approved U.S. crofelemer use today, these extra programs look like Dogs in a BCG Matrix if data do not improve fast. That makes them prime deprioritization candidates.
- 1 approved U.S. use
- Exploratory uses still unproven
- High spend, low traction
- Cut if data stay weak
Jaguar Health Crofelemer Looks Like a Low-Return Bet
Jaguar Health, Inc.'s Dogs are crofelemer uses with weak share, thin proof, and costly selling effort. IBS-D is crowded, with about 10% to 15% of U.S. adults affected and rivals like Xifaxan and Viberzi already entrenched, while crofelemer still has only 1 approved U.S. use. These programs look low-return unless data improve fast.
| Use | Why Dog | Signal |
|---|---|---|
| Crofelemer GI uses | Low traction | Deprioritize |
Question Marks
Crofelemer oncology supportive care
Crofelemer is Jaguar Health, Inc.'s biggest upside theme, because oncology supportive care is a large and growing diarrhea-management market, but Jaguar Health, Inc. still has very low share. The product is not yet a scaled oncology standard, so winning share will need more clinical data, FDA/regulatory work, and cash. That makes it a Question Mark: high upside, but also high spend and execution risk.
Crofelemer short bowel expansion
Crofelemer’s short bowel expansion targets a rare, high-need SBS with intestinal failure group, where many patients still rely on parenteral support for survival. Jaguar Health, Inc. is still building the clinical and payer case, so this is a Question Mark in BCG terms, not a proven cash driver. The upside is real, but commercial conversion is still unproven.
Crofelemer pediatric orphan expansion
Crofelemer’s pediatric orphan expansion is a Question Mark for Jaguar Health, Inc.: rare-disease use can bring orphan pricing, tax credits, and 7-year U.S. exclusivity. The upside is attractive because unmet need is high, but the addressable market is still early and small. It is not yet a proven scale story, so uptake, reimbursement, and label expansion will decide the result.
Lechlemer development path
Lechlemer is still a development asset, not a commercial product, so in Jaguar Health, Inc.'s BCG view it fits the Question Marks bucket. Cholera demand is episodic and outbreak-driven, so any share has to be created in a market that is not steady. The program looks promising, but the payoff is still uncertain.
- Precommercial asset
- Outbreak-linked demand
- Share must be built
- High upside, high risk
Pipeline beyond current labels
Jaguar Health, Inc.'s pipeline beyond current labels is still a classic question mark: it can add value only if clinical data and FDA outcomes land well, and the company still needs cash to keep programs moving. In its latest filing, Jaguar Health, Inc. reported about $10.6 million in revenue for 2024 and a net loss of about $28.0 million, which shows how execution risk and funding risk stay tied together.
- Value needs positive trial data.
- Regulatory wins are not guaranteed.
- Financing remains a key constraint.
- Until then, it stays a question mark.
Jaguar Health's upside hinges on crofelemer and lechlemer, but funding remains tight
Jaguar Health, Inc.'s question marks are still crofelemer label expansions and lechlemer, because each one has real market upside but no proven scale yet. The company reported about $10.6 million in 2024 revenue and a $28.0 million net loss, so funding pressure still shapes execution. These programs can re-rate only if clinical data, FDA progress, and reimbursement improve.
| Item | Signal |
|---|---|
| Crofelemer | High upside, low share |
| Lechlemer | Precommercial |
| 2024 revenue | $10.6M |
| 2024 net loss | $28.0M |
Disclaimer
All information, articles, and product details provided on this website are for general informational and educational purposes only. We do not claim any ownership over, nor do we intend to infringe upon, any trademarks, copyrights, logos, brand names, or other intellectual property mentioned or depicted on this site. Such intellectual property remains the property of its respective owners, and any references here are made solely for identification or informational purposes, without implying any affiliation, endorsement, or partnership.
We make no representations or warranties, express or implied, regarding the accuracy, completeness, or suitability of any content or products presented. Nothing on this website should be construed as legal, tax, investment, financial, medical, or other professional advice. In addition, no part of this site—including articles or product references—constitutes a solicitation, recommendation, endorsement, advertisement, or offer to buy or sell any securities, franchises, or other financial instruments, particularly in jurisdictions where such activity would be unlawful.
All content is of a general nature and may not address the specific circumstances of any individual or entity. It is not a substitute for professional advice or services. Any actions you take based on the information provided here are strictly at your own risk. You accept full responsibility for any decisions or outcomes arising from your use of this website and agree to release us from any liability in connection with your use of, or reliance upon, the content or products found herein.